Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Authors
Ahmad, SQian, W
Ellis, S
Mason, Elaine
Khattak, M
Gupta, A
Shaw, H
Quinton, A
Kovarikova, J
Thillai, K
Rao, A
Board, R
Nobes, J
Dalgleish, A
Grumett, S
Maraveyas, A
Danson, S
Talbot, T
Harries, M
Marples, M
Plummer, R
Kumar, S
Nathan, P
Middleton, M
Larkin, J
Lorigan, Paul C
Wheater, M
Ottensmeier, C
Corrie, P
Affiliation
Department of Oncology Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, CambridgeIssue Date
2015-10
Metadata
Show full item recordAbstract
Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patient data using a prespecified variable fields datasheet. Data collected were baseline patient characteristics, treatment delivered, toxicity, response, progression-free survival and overall survival (OS). Data were received for 193 previously treated metastatic melanoma patients, whose primary sites were cutaneous (82%), uveal (8%), mucosal (2%), acral (3%) or unknown (5%). At baseline, 88% of patients had a performance status (PS) of 0-1 and 20% had brain metastases. Of the patients, 53% received all four planned cycles of ipilimumab; the most common reason for stopping early was disease progression, including death from melanoma. Toxicity was recorded for 171 patients, 30% of whom experienced an adverse event of grade 3 or higher, the most common being diarrhoea (13%) and fatigue (9%). At a median follow-up of 23 months, the median progression-free survival and OS were 2.8 and 6.1 months, respectively; the 1-year and 2-year OS rates were 31 and 14.8%, respectively. The 2-year OS was significantly lower for patients with poorer PS (P<0.0001), low albumin concentrations (P<0.0001), the presence of brain metastases (P=0.007) and lactate dehydrogenase levels more than two times the upper limit of normal (P<0.0001) at baseline. These baseline characteristics are negative predictors of benefit from ipilimumab and should be taken into consideration before prescription.Citation
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. 2015, 25 (5):432-42 Melanoma ResJournal
Melanoma ResearchDOI
10.1097/CMR.0000000000000185PubMed ID
26225580Type
ArticleLanguage
enISSN
1473-5636ae974a485f413a2113503eed53cd6c53
10.1097/CMR.0000000000000185
Scopus Count
Collections
Related articles
- Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.
- Authors: Berrocal A, Arance A, Lopez Martin JA, Soriano V, Muñoz E, Alonso L, Espinosa E, Lopez Criado P, Valdivia J, Martin Algarra S, Spanish Melanoma Group
- Issue date: 2014 Dec
- Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
- Authors: Alexander M, Mellor JD, McArthur G, Kee D
- Issue date: 2014 Jul 7
- Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.
- Authors: Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quaglino P, Carnevale Schianca F, Mandalà M, Di Guardo L, Del Vecchio M
- Issue date: 2014 Apr 2
- Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
- Authors: Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU
- Issue date: 2014 May
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
- Authors: Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA
- Issue date: 2013 Nov